TB Clinical Research: Training the Next Generation

描述(由申请人提供)：研究人员Carol Dukes Hamilton医学博士将使用NIH K24基金帮助培训未来几代临床科学家从事结核病(TB)研究。与任何其他传染病相比，结核病造成的死亡人数更多。汉密尔顿博士的长期研究目标是优化成人和儿童的活动性和潜伏性结核病的治疗策略。她的计划的优势包括持续资助和积极参与疾控中心资助的结核病试验联盟临床试验小组，疾控中心资助的结核病流行病学研究联盟，以及NHLBI资助的结核病易感性遗传学研究。这些资助的项目构成了她的研究事业的基础。它们与她作为北卡罗来纳州结核病控制项目医务主任提供的机会完美结合，为受试者提供了招募受试者、临床和流行病学研究培训的途径，并提供了根据调查结果实施改革的机会。 汉密尔顿博士的结核病研究项目的优势在于，她同时使用临床试验和流行病学研究来实现她的研究目标。学员可以在培训期间采用其中一种方法。教学课程是汉密尔顿博士指导计划中不可或缺的一部分，它能获得临床研究科学硕士学位或公共卫生硕士学位。汉密尔顿博士还将利用这些资源加强她基于经验的研究能力。汉密尔顿博士的研究计划包括对结核病试验联盟临床试验的描述，“研究26”，将每天9个月的异烟肼治疗与每周12剂异烟肼加利福喷丁治疗潜在结核病感染的有效性进行比较。计划的和潜在的次级研究和二次分析为学员发起的研究项目提供了肥沃的基础。该研究计划还包括她的NHLBI资助的对可能导致人类结核病易感性的候选基因的遗传流行病学研究。她与杜克人类遗传学中心的合作是她希望在她的分枝杆菌研究项目中培养翻译研究的一个例子。

DESCRIPTION (provided by applicant): The Investigator, Carol Dukes Hamilton, M.D., will use NIH K24 funding to help train future generations of clinical-scientists for a career in tuberculosis (TB) research. TB is responsible for more human deaths than any other infectious disease. Dr. Hamilton's long-term research goals are to optimize strategies for treating active and latent TB in adults and children. Strengths of her program include ongoing funding and active participation in the CDC-funded TB Trials Consortium clinical trials group, the CDC-funded TB Epidemiologic Studies Consortium, and an NHLBI-funded study of genetics of TB susceptibility. These funded programs form the basis of her research enterprise. They combine perfectly with the opportunities afforded by her position as the Medical Director for North Carolina's TB Control Program, providing an avenue for subject recruitment, clinical and epidemiologic research training for advisees, and the opportunity to implement changes based on the findings. The strength of Dr. Hamilton's TB research program is that she employs both clinical trials and epidemiologic studies to attain her research goals. Trainees can tap into one or the other methodologies during their training. Didactic course work leading to either a Masters in Clinical Research Science or Public Health is an integral part of Dr. Hamilton's mentoring plan. Dr. Hamilton will also strengthen her experiencebased research capability using these resources. Dr. Hamilton's research plan includes a description of the TB Trials Consortium clinical trial, "Study 26", comparing the effectiveness of 9 months of daily isoniazid therapy to 12 doses of weekly isoniazid plus rifapentine, for treatment of latent TB infection. Planned and potential sub-studies and secondary analyses provide fertile substrate for trainee-initiated research projects. The research plan also includes her NHLBI funded genetic epidemiologic study of candidate genes that may contribute to human TB susceptibility. Her work with the Duke Center for Human Genetics is an example of translational research she hopes to foster within her mycobacteria research program.